Alexandra Lansky
Latest contributions
Treatment and prognostic stratification of ACS patients with cardiogenic shock
21 May 2025 – From EuroPCR 2025
This session focuses on treatment and prognostic stratification in ACS patients complicated by cardiogenic shock. Topics include mechanical CPR device performance, SCAI shock grade dynamics, hemorrhagic event predictors, ECMO-related strategies, and evaluation of BCIS conveyance algorithms for out-of-hospital cardiac arrest.
How a new generation of coronary sinus reducer can significantly expand treatment options for patients with coronary microvascular dysfunction
21 May 2025 – From EuroPCR 2025
Discover the latest on managing coronary microvascular dysfunction (CMD) with insights from EuroPCR 2025. This session explores how physiology testing helps identify CMD endotypes in the cathlab and highlights the limitations of ETT for patients experiencing angina or dyspnea at rest. Learn about the A-FLUX coronary...
Cardiogenic shock in women : different cause, different treatment
15 May 2024 – From EuroPCR 2024
This session will feature selected EuroPCR 2024 Clinical Case submissions focused on cardiogenic shock in women. Attendees will have the opportunity to learn about the proposed diagnoses and treatments, as well as the actual outcomes, for these challenging cases. The session will also include discussions and...
Cardiovascular intervention for chronic heart failure: where do we stand?
15 May 2024 – From EuroPCR 2024
Hotline: advances in coronary physiology
14 May 2024 – From EuroPCR 2024
This hotline session explores the latest advancements in coronary physiology and their implications for percutaneous coronary intervention (PCI). Topics covered include the influence of pathophysiological patterns of coronary artery disease on the safety and efficacy of PCI, the prognostic value of myocardial ischemic burden in STEMI...
Hot TAVI topics - Cerebral embolic protection
27 Nov 2022 – From PCR London Valves 2022
Consult this session to learn more about the latest data concerning cerebral embolic protection (CEP) in TAVI, to find out about currently available and emerging embolic protection devices and to get a better understanding of variations in head and neck vessel anatomy and tips and tricks...
TRISCEND, ACURATE neo2, the LuX-Valve System: Top Late-Breaking Trials from PCR London Vaves 2022
27 Nov 2022 – From PCR London Valves 2022
Discover a selection of PCR London Valves 2022 Late-Breaking Trial submissions and learn more about the latest evidence evidence concerning new transcatheter valve devices, emerging innovative devices as well as highlighted content from the EuroIntervention journal.
EuroPCR 2022 Hotlines / Late-Breaking Trials in coronary physiology: DECISION QFR, INOCA, and PROPHET-FFR
17 May 2022 – From EuroPCR 2022
Find out more about various studies & registries in coronary physiology! Angiography-derived coronary microcirculatory assessment in INOCA patients, Heart Team decision-making based on angiography-derived FFR: DECISION QFR, and safety and efficacy of post-PCI physiological assessment: PROPHET-FFR.
A randomised study comparing imaging guided implantation of Orsiro and Xience - CASTLE study
20 May 2021 – From EuroPCR 2021
Watch this LBT session, which was originally presented during EuroPCR 2021, to find out more about the CASTLE study, whose aim is to access the results of two types of DES implanted with image guidance in all-comers.
One-year results from the FUTURE-II trial
19 May 2021 – From EuroPCR 2021
This LBT session, which was originally presented during EuroPCR 2021, deals with the FUTURE-II study on the new generation of bioresorbable scaffolds, providing comparative safety and efficacy evidence of the thinner-strut PLLA-based BRS in the treatment of patients with noncomplex coronary lesions.
Leading with evidence, latest clinical outcomes update for Firesorb, Firehawk and VitaFlow
19 May 2021 – From EuroPCR 2021
Watch this session presented by Alexandra Lansky, Andreas Baumbauch, Junbo Ge and Bo Xu in order to learn about the one-year results from a pivotal RCT (FUTURE II), the four-year results from TARGET AC, and the four-year results from VitaFlow transcatheter aortic valve system in patients with severe aortic...
